The biopharmaceutical world is abuzz as Innovent Biologics (HKEX: 01801) gears up to present a slate of groundbreaking research at the American Diabetes Association’s (ADA) 85th Scientific Sessions. The company, known for its focus on innovative treatments across oncology, autoimmune, and metabolic diseases, is set to showcase novel findings on its pipeline, including an antibody-peptide conjugate and its promising dual-agonist treatment, mazdutide.
The ADA conference, a premier event for diabetes research, will be the stage for Innovent to unveil data from preclinical studies and investigator-initiated trials, offering a glimpse into the future of metabolic disease treatment.
First up is a peek at IBI3030, a novel anti-PCSK9 antibody conjugated with innovative peptides. This cutting-edge approach aims to deliver a multi-pronged attack on cardiovascular risk factors.
Abstract Number: 1886-LB
Presentation: Poster
Time: Sunday, June 22, 2025, 12:30 P.M. – 1:30 P.M. CDT
Location: Poster Hall (Hall F1)
Author: Dr. Decheng Ren, Innovent Biologics
The preliminary data suggests IBI3030 significantly improves a range of cardiovascular metabolic risk indicators through a multi-target synergistic effect. The antibody component of IBI3030 is designed to inhibit LDL receptor degradation, thus reducing LDL-c levels. Simultaneously, the triple-target agonist peptide activates GLP-1R/GCGR/GIPR receptors, bolstering the capacity for hepatic fatty acid oxidation. Early stage signals indicate IBI3030 could outperform existing therapies.
But the real buzz may surround mazdutide, Innovent’s dual glucagon (GCG)/GLP-1 receptor agonist, which has quickly become a focal point for the scientific community. The ADA presentations will delve into mazdutide’s potential for liver fat reduction, fibrosis improvement, liver fat accumulation alleviation, and serum uric acid reduction. Some studies that will be presented:
1. **Mazdutide vs. Semaglutide: Unpacking the Liver Fat Battle**
Topic: The Dual Glucagon and Glucagon-Like Peptide 1 Receptor Agonist Mazdutide Outbalanced Glucagon-Like Peptide 1 Receptor Agonist Semaglutide Monotherapy in Improving Mice Liver Fat Accumulation
Abstract Number: 777-P
Presentation: Poster
Time: Sunday, June 22, 2025, 12:30 P.M. – 1:30 P.M. CDT
Location: Poster Hall (Hall F1)
Author: Tianpei Hong, Peking University Third Hospital
This study suggests that mazdutide could be superior to Semaglutide in decreasing liver fat. Data shows that it activates key pathways related to fatty acid degradation, potentially leading to a more effective treatment strategy.
2. **Mazdutide’s Impact on MASH and Hepatic Fibrosis**
Topic: Mazdutide，a GCG/GLP-1R dual-agonist, alleviates MASH and hepatic fibrosis
Abstract Number: 1616-P
Presentation: Poster
Time: Sunday, June 22, 2025, 12:30 P.M. – 1:30 P.M. CDT
Location: Poster Hall (Hall F1)
Author: Ling Li, Zhongda Hospital, School of Medicine, Southeast University
3. **Mazdutide and its ability to Alleviate Hyperuricemia**
Topic: Mazdutide, a Dual GLP-1R/GCGR Agonist, Alleviates Hyperuricemia by Modulating Hepatic Energy and Lipid Metabolism and Inhibiting Purine Pathways
Abstract Number: 775-P
Presentation: Poster
Time: Sunday, June 22, 2025. 12:30 P.M.- 1:30 P.M. CDT
Location: Poster Hall (Hall F1)
Author: Hongwei Jiang, The First Affiliated Hospital, and College of Clinical Medicine of Henan University of Science and Technology
Here, researchers have found that mazdutide can significantly lower serum uric acid levels, primarily by boosting fatty acid oxidation within the liver. This could indicate a metabolic shift that helps reduce the precursors of uric acid.
Dr. Lei Qian, from Innovent Biologics, sounded optimistic, stating, “We are delighted to see mazdutide’s mechanism exploration studies featured extensively at the ADA conference. The growing body of scientific evidence will further validate mazdutide’s differentiated profile as a next-generation GCG/GLP-1 dual receptor agonist, particularly in liver fat and serum urine reduction. Moreover, in the field of cardiovascular and metabolic diseases, Innovent is dedicated to developing next-generation innovative therapies. This includes IBI3030 (PCSK9-GGG), a novel modality with a unique MoA that embodies an innovative ‘one-drug, multiple-effects’ therapeutic strategy. IBI3030 has the potential to deliver comprehensive therapeutic benefits and meaningfully improve outcomes for more patients worldwide.”
Mazdutide, also known as IBI362, is licensed to Innovent by Eli Lilly. As a mammalian oxyntomodulin (OXM) analogue, mazdutide is being developed to promote insulin secretion, lower blood glucose, and reduce body weight by activating the glucagon receptor. The company has two NDAs for mazdutide accepted for review by NMPA for long-term weight management in adults with obesity or overweight and for glycemic control in adults with type 2 diabetes (T2D).
Currently, mazdutide is in seven Phase 3 clinical studies, with four more in the pipeline. The company is also looking into new clinical trials, including trials in adolescents with obesity and metabolic dysfunction-associated steatohepatitis (MASH) and heart failure with preserved ejection fraction (HFpEF).
Innovent Biologics, founded in 2011, is a leading biopharmaceutical company focused on bringing affordable, high-quality treatments to patients worldwide. With [15/16] products launched, [3/2] new drug applications under regulatory review, and a robust clinical trial pipeline, Innovent is making waves in the industry.
Original article, Author: Jam. If you wish to reprint this article, please indicate the source:https://aicnbc.com/3053.html
